Document Classification

Section Type: RESULTS

Text: At day 365, the following response rates were observed for abatacept and infliximab, respectively : American College of Rheumatology (ACR) 20, 72. 4 and 55. 8 % ; ACR 50, 45. 5 and 36. 4 % ; ACR 70, 26. 3 and 20. 6 % ; low disease activity score (LDAS), 35. 3 and 22. 4 % ; DAS28-defined remission, 18. 7 and 12. 2 % ; good European League Against Rheumatism (EULAR) responses, 32. 0 and 18. 5 % ; and Health Assessment Questionnaire Disability Index (HAQ-DI), 57. 7 and 52. 7 %.